We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Poolbeg Pharma Plc | POLB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.10 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.10 | 5.10 | 5.10 | 5.10 | 5.10 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 10/1/2025 09:32 by pogue Re the reason for the rise here see link below. I have now confirmed to myself Peterrr3 is a deramper. The information is obvious for him not to work it out after all his posting about looking into POLB and advising they were looking for a fundraise.A two second google on Gilead drugs and you goto the cancer ones, obviously, and you see 2 have CRS as a side effect. Clearly Gilead were one of the companies talking to POLB re doing trials with their drugs and POLB. So now late this year Phase 2 of POLB001 will go ahead. If you struggle to find info on the trial date try reading this presentation, again not hard to find the info if you do any research page 30 has the clinical milestones chart. |
Posted at 09/1/2025 21:43 by troutisout I always worked on POLB being half the price of HVO and it was roughly that for a long while, up until last year when HVO outperformed that, POLB once got back to half the value but suffered far more last year then HVO and even now the drop for POLB was far more than HVO has suffered, in fact POLB is less than a third of the HVO price, but your hatred for one and love for another abounds.....Are you CF in disguise?free stock charts from uk.advfn.com free stock charts from uk.advfn.com free stock charts from uk.advfn.com |
Posted at 05/1/2025 22:14 by 1gw That strikes me as a good article as far as assessment of Polb-Hook goes, and not too far away from some of the commentary here. Hook gets some cash from Polb and some more from the raise, while Polb gets on to Nasdaq and gets a shot at a bigger payback if any of the trials impress big pharma sufficiently, or if the already-partnered assets (with Gilead & Roche) go far enough. But still high risk given the funding requirements."The Hookipa merger gives Poolbeg a few more seats at the table, if not a guarantee of the jackpot." [In the Ireland section] |
Posted at 05/1/2025 12:54 by chica1 POLB as someone said is a zombie stock.It will now trade in line with HOOK's fluctuations. There are 2 problems is see short term The CVR's make HOOK the more attractive share to buy so POLB will trade at an extra discount. And The $30 million capital raise is higher than the current market cap of HOOK. + No news on HOOK's trails until end of 2025. The positives for POLB is now they have more bites of the cherry and its probably a good thing. |
Posted at 03/1/2025 13:14 by toby hall a post from the other sideDingodog1 ..Today 13:03 My take is that HOOK is an appropriate "vessel" that POLB can use to access NASDAQ. It is sufficiently "distressed" that POLB can get a sizeable level of equity (even post dilution) to allow a tangiable return if should POLB take off. Arguably POLB001 is the golden ticket from POLB's perspective, and bolting on to HOOK effectively gives POLB access to the capital markets of the US, which may value it more favourably. Yes HOOK may be coming along for the ride as the vessel, but i wouldnt be too focused on what HOOK brings to the table other than the vessel it provides. AIM values POLB at, say, £40m. Nasdaq MAY value it at £400m+. That is a ten bag, albeit diluted to incorporate HOOK and the fund raise. My view is that Cathal is looking at future value, not immediate value. Many on here have said before that AIM is a cesspit etc and thus the value for POLB may not be truly recognised. Taking POLB to the nasdaq via HOOK MAY unlock that value. IF the new group is valued at £400m on nasdaq i dont think anyone will complain. As i say, i think HOOK is the vessel, not the perfect partner for us to tap into their offerings. How much would it cost to float POLB on nasdaq? Is that even possible? How long would it take? I think this route is considered to accelerate proceesings whilst recognising value. All imo, and the silence of the BOD and CF doesnt help |
Posted at 03/1/2025 10:45 by pogue peterrr3I agree they did not find a distressed NASDAQ company to buy so are now merging with one with some nice assets and income based on partnership with a Gilead who have a large stake in HOOK so must be confident of HB-400 and HB-500 coming through the trials this year with the resultant cash coming to HOOK if that happens for progressing the drug. I didn’t see anyone attempting to pump the price this year at POLB. Presentations were rare you must be thinking of another company. 2 Pharma provided the drugs for trials on POLB001 and it was tested with animals so they did interest pharma in POLB001. AI dataset found molecules to look at. Time will tell too early there yet I suggest. Management have completed a NASDAQ listing as promised to get away from AIM as many other companies are doing to get to a working exchange. I suggest that is the reason for this merger not to a way to extract value. Working hard looking for negatives I see. I think you are twisting the facts a little. |
Posted at 09/12/2024 07:25 by burtond1 Good morning,I hope all is well and please see link to RNS Reach issued by Poolbeg this morning: https://www.londonst |
Posted at 13/10/2024 08:54 by pogue Peterrr3I go to plenty events to window shop, going to an event does not mean there is a fundraise going to happen, I suggest you are taking one presentation out of context and extrapolating to the moon. I don’t see where they need the funds to be honest. They started out 3 years ago with around £20 million and now have around £10 million and are trailing POLB001 with 2 pharma companies’ drugs which suggests they are in advanced talks as if they goto human trial, they have done the In Vivo animal trial, there would have to be a contract signed setting out the partnership/selling deal should the result be positive as is normal in these situations in industry. No pharma company would want to increase the value of a 3rd party drug by proving it successful without having a price fixed beforehand. Why fundraise when you are that close to a massive monetisation of your lead asset? Why are they trying to find an orphan drug to sell? Well to make money perhaps? POLB have a pipeline of drugs they develop and sell/partner. Pentoxifylline has past phase II so they don’t need to put it through a trial. I don’t know what the deal will be with the owner but I cannot see POLB buying it unless they have a buyer. I suggest the most likely is a partnership where POLB help sell the drug and share in the profits. This is a capital light company they don’t spend money unless they have to bringing on drugs, have you seen the very small quantities of cash they have spent on the existing drugs in the pipeline? The fact they have spent only £10 million or so over 3 years is a clue. As I said I have listened to the Liam Trimble go on about POLB’s encapsulation tech being used in a trail later this year all 43 seconds off it and did not get excited about at the time as an oral encapsulation trial was being planned from the beginning of this year and was initially down to happen July/August so not seeing what the issue is, nothing new in it. The cost will be small and is being tested for use with another company’s drug they will contribute in some way same as those pharmas running the POLB001 trials did. The trial is very simple for encapsulation. Volunteer comes into medical establishment, pops a pill come backs next day to get a blood test to see if the drug has dispersed in their system, you really think they need a fundraise for this and it hasn’t been planned for? It is not the drug that’s being tested its oral encapsulation so not dangerous or expensive do you really think a sudden fundraise is needed for that as it has been planned for for a long time? As I said POLB does not have an obesity drug it’s the encapsulation that is being trailed. Should the trial work then there is a vast market out there for oral encapsulation way outside obesity drugs. Really cant see what you are going on about there. So to summarise why do you think they need a fundraise when they are getting close to a deal on POLB001? Oral encapsulation has been planned for trial for a long time and is not expensive to do. Pentoxifylline does not belong to POLB, they have an option on it and is past phase II so what cash do they need to spend as the option will more than likely be on a deal to sell in partnership with current owner and they dont need to conclude the deal if they see no buyers. |
Posted at 02/7/2024 11:38 by pogue peterr3I will spell it out as I feel you were listening to the wrong bits there. The lead asset of POLB is POLB001 and will be the first monetized. 2 pharmas are interested in it as their new very powerful cancer drugs have the side effect of cytokine storms. Cytokline storms mean that patients tie up hospital beds in cancer units thus reducing the amount of drugs that can be administered so huge incentive to find a drug that prevents them happening, like POLB001. Hugh incentive there for a phamra to partner with POLB if POLB001 works. Now as a stand alone drug POLB001 does the job all they have to do is prove it works whilst other drugs are in a patients system. The 2 pharmas have already given POLB the drugs, worth £millions, to run the trial and will pay for the trial as the market for their drug is 10s of $billions. We await the trial date how long do you think the pharmas are going to wait with a prize of that size? Now the other part you need to research is what normally happens in these situations ie a drug going to trial with another and what the trial contract normally says baring in mind that if it proves successful the value of POLB001 goes through the roof. Clue the contract has a section on that and I strongly suggest that is the reason for the delay as its a very important section.. Sorry if very direct but you have missed the point completely of what is happening and this board has so many halfwit derampers who avoid basic facts that I treat posters I dont know with suspicion. |
Posted at 07/2/2024 18:54 by troutisout We have all seen the great rise in HVO over the last 7 months, starting with contract wins in late June and July, then the positive trading update at the end of July and of course, what was the start of Institutional buying.Before that POLB mirrored HVO quite closely, deviating a little every now and then and then one or the other adjusting back. POLB showed the way in late Summer/Autumn 2022 with HVO mirroring the moves several weeks later. Then HVO leapt ahead of POLB in the late Summer/Autumn 2023, but the news of the Amryt team joining propelled POLB back up there again in November. As we went into the Christmas period and the New Year HVO has hit the rocket boosters with more contract wins and a really good TU. POLB has dithered and dropped slightly. I don't think the relationship between the two has broken (although the II buying in HVO will have diluted the relationship where many of the holders of HVO also held POLB). So we wait to see if POLB catches up again, it certainly looks a few weeks behind but the correlation has been strong up to now.... POLB black, HVO Blue, HVO overlaid on POLB from the first day of POLB trading free stock charts from uk.advfn.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
